Organon & Co.

NYSE:OGN

Drug Manufacturers - General

Healthcare
$13.92 +0.04%

+$0.01 today

Market cap
$3.66B
Beta
1.54
P/E (TTM)
14.2
EPS (TTM)
$0.94
Dividend yield
0.60%
52W Low $5.69High $13.49

Volume 3.90M

Average 8.57M

OGN Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Organon & Co.NYSE: OGN

Net Margin · Q3 FY2026 · quarter ended Sep 2026

Net margin holds steady near 10.4%

Net margin was 10.4% in Q3 FY2026, up 0.4 pp from a year earlier. On a trailing-twelve-month basis it was 3.5%, down 4.5 pp year over year. Over 3 fiscal years it narrowed by 11.8 pp.

Context

  • Net margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 2 analysts of 14.3% for the fiscal year ending Dec 2026, up from 3.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
10.4%+3.5 pp QoQ
Last fiscal yearDec 2025
3.0%-10.5 pp YoY
LTMSep 2026
3.5%-4.5 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.4 pp+27.3 pp+26.9 pp
1 year-10.5 pp+11.3 pp+21.7 pp
3 years-11.8 pp+12.6 pp+24.4 pp
5 years+12.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
3.0%
Year-over-year change
-10.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How OGN compares with its peers on the latest reported figures

  • OGN's LTM Sep 2026 net margin of 3.5% is the 6th highest of the 10 companies compared; the peer median is 4.5%.
  • Its year-over-year change of -4.5 pp is the 7th highest of 10, against a peer median of -0.8 pp.
  • Over three fiscal years its change of -11.8 pp compares with a peer median of -0.2 pp.
OGN Competitors Peer median
Net Margin for OGN and competitors
Company Period LTM level YoY 3-year change
AUPHAurinia Pharmaceuticals Inc.LTM Jun 2026100.8% +77.5 pp+182.2 pp
HRMYHarmony Biosciences Holdings, Inc.LTM Jun 202618.9% -4.5 pp-23.2 pp
MDPediatrix Medical Group, Inc.LTM Sep 20267.7% -0.8 pp+5.3 pp
PAHCPhibro Animal Health CorporationLTM Mar 20266.3% +3.7 pp-1.5 pp
GRDNGuardian Pharmacy Services, Inc.LTM Jun 20264.5% +10.7 pp-0.5 pp
OGNOrganon & Co.LTM Sep 20263.5% -4.5 pp-11.8 pp
SEMSelect Medical Holdings CorporationLTM Mar 20262.4% -1.6 pp+0.2 pp
ALVOAlvotechLTM Mar 2026-14.4% -30.9 pp+623.3 pp
NUVBNuvation Bio Inc.LTM Jun 2026-88.2% +1325.2 pp—
TLRYTilray Brands, Inc.LTM Feb 2026-156.2% -37.9 pp-190.4 pp
Peer median (excluding OGN) 4.5%-0.8 pp-0.2 pp

Competitors are the stored peer set for OGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.3B6.17B6.26B6.4B6.22B
Cost of Revenue2.38B2.29B2.52B2.69B2.85B
Gross Profit3.92B3.88B3.75B3.72B3.36B
Gross Margin62.2%62.8%59.8%58.0%54.1%
Research & Development443M471M528M469M366M
Selling, General & Admin1.67B1.7B1.89B1.76B1.71B
Operating Expenses2.01B2.18B2.42B2.23B2.09B
Depreciation & Amortization195M212M236M277M361M
EBITDA1.98B1.76B1.44B1.6B1.29B
EBITDA Margin31.4%28.4%22.9%25.1%20.8%
Operating Income1.92B1.71B1.33B1.49B1.29B
Operating Margin30.4%27.6%21.2%23.2%20.7%
Interest Income00000
Interest Expense258M422M527M520M504M
Other Income / Expenses(386M)(583M)(654M)(679M)(860M)
Income Before Tax1.53B1.12B673M807M425M
Pre-Tax Margin24.3%18.2%10.7%12.6%6.8%
Income Tax Expense178M205M(350M)(57M)238M
Net Income1.35B917M1.02B864M187M
Net Margin21.4%14.9%16.3%13.5%3.0%
EPS (Basic)5.333.614.013.360.72
EPS (Diluted)5.333.593.993.330.72
Weighted Avg Shares253.55M254.08M255.24M257.05M259.5M
Weighted Avg Shares (Diluted)253.55M255.17M256.27M259.15M260.76M

Organon & Co.

NYSE:OGN

Intrinsic Alpha fair value

Locked

Current Price

$13.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.